Ethnic Bridging: The Who, the When, the Why
In the dynamic realm of clinical drug development, a new star is rising: Ethnic Bridging clinical trials, also known as ethnobridging or Asian bridging...
In the dynamic realm of clinical drug development, a new star is rising: Ethnic Bridging clinical trials, also known as ethnobridging or Asian bridging...
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo...
Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical...
Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this...
Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...
Salt Lake City, May 3, 2022 /GlobeNewswire/ — CenExel announces the acquisition of iResearch (“CenExel iResearch”), a leading multi-specialty research site business with locations in...
Salt Lake City, January 11, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site...
Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research...
Salt Lake City, August 19, 2021 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Advanced Memory Research Institute (“CenExel AMRI”), the largest...